Can a simple bone marrow test predict who will beat High-Risk leukemia?
NCT ID NCT02583893
First seen May 29, 2026 · Last updated May 29, 2026
Summary
This study looked at 39 adults with high-risk acute myeloid leukemia (AML) to see if certain markers in their bone marrow could predict how well they would respond to a combination of the drug sirolimus and standard chemotherapy. The goal was to find out if changes in these markers early in treatment could tell doctors which patients are likely to go into remission. The study did not test a new treatment but aimed to improve how we predict treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ADULT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.